# GUNS (NCT04812366)

> Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: apalutamide; apalutamide plus abiraterone plus prednisone; abiraterone plus prednisone
- Indication: high-risk localized prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04812366
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: University of British Columbia
- Conditions: Prostate Cancer
- Interventions: Apalutamide 60mg Tab; Abiraterone Acetate 250mg; Prednisone 5mg Tab; Docetaxel; Niraparib 100mg Oral Capsule; Atezolizumab; Tazemetostat Pill; Capivasertib
- Enrollment: 315
- Primary outcome: Complete Pathologic Response (pCR)
- Primary outcome: Pathological Minimal Residual Disease (pMRD)

## Indexed commentary on GUNS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 23
- YouTube: 4
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=guns-nct04812366

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04812366", "email": "<work email>"}; the inbox owner confirms by the emailed link.